Mycophenolate

Pharmacodynamic Laboratory, Mississippi State University, 2017

Mycophenolate mofetil is the synthesized prodrug form of mycophenolic acid, a selective and reversible inhibitor of inosine monophosphate dehydrogenase, an enzyme that controls the rate of synthesis of guanine monophosphate in the *de novo* pathway of purine synthesis. Mycophenolate mofetil is a fermentation product derived from fungi in the *Penicillium* group. Mycophenolic acid inhibits B and T cell proliferation, and decreases antibody production. Mycophenolate mofetil is primarily used in human medicine for prevention of rejection of transplanted organs, although it also used to treat immune-mediated diseases such as systemic lupus erythematosus, immune-mediated hemolytic anemia (IMHA), immune-mediated thrombocytopenia and pemphigus vulgaris. Mycophenolate mofetil is often used in the place of azathioprine in human medicine and, since they have similar mechanisms of action, the two drugs should not be used together.

The original proprietary mycophenolate mofetil product, CellCept®, and the closely related mycophenolate sodium product, Myfortic®, were expensive, and as a result the products only achieved limited usage in small animal medicine. However, more recently, the availability of much cheaper generic alternatives has led to a greatly increased usage of mycophenolate mofetil in small animal patients. A single 250 mg CellCept® capsule currently costs around $9, whereas the equivalent generic 250 mg capsule costs less than 50c. An oral suspension version of mycophenolate mofetil (200 mg/ml) is available for more convenient dosing in smaller patients. Successful usage of mycophenolate mofetil in a small animal patient with naturally-occurring disease was first described in a dog with acquired myasthenia gravis. Much of the subsequent anecdotal usage of mycophenolate mofetil for a variety of different immune-mediated diseases was similar to the dosing reported in this original paper. Mycophenolate mofetil is also available in an injectable form, and the intravenous use of the drug has been described during the successful initial stabilization of three dogs with acquired myasthenia gravis that could not tolerate oral medications. Ironically, a more recent case report of 15 dogs with acquired myasthenia gravis treated with mycophenolate mofetil reported that the drug was ineffective at attaining clinical remission. Recent papers reporting the use of mycophenolate mofetil in dogs with IMHA or IMT have shown variable but sometimes promising results: while individual dogs appear to respond to therapy, overall response rates in some papers were are no better than those seen with more established drugs, and gastrointestinal side effects can often limit clinical usefulness of the drug. Recently, several retrospective case series reporting the use of mycophenolate mofetil for the treatment of meningitis of unknown origin in dogs showed promising results: interestingly, mycophenolate has also shown some promise in treating multiple sclerosis in people, where it is believed to have a neuroprotective effect. Mycophenolate was also recently shown to be of benefit in the treatment of autoimmune skin diseases in dogs. Mycophenolate has been suggested for the treatment of immune glomerulonephritis in the dog. The clinical effectiveness of mycophenolate for treating most immune disease in dogs has not yet been well-established. The extensive protein binding of the drug, which can vary widely from patient to patient, may explain variable and unpredictable responses to drug, as could variations in drug metabolite profiles produced in individual profiles. Promisingly, recently completed work in our laboratory has established that mycophenolate mofetil at maximally tolerated doses (in individual dogs, this dose varies between 10 mg/kg and 20 mg/kg twice daily) does significantly inhibit lymphocyte proliferation in normal dogs, although this effect is not observed until two weeks into therapy, suggesting a delayed response to the drug.

A recommended starting dose for mycophenolate mofetil in dogs is 10-20 mg/kg twice daily, although often gastrointestinal signs (particularly vomiting and, especially, severe diarrhea) at the higher end of the dose rate will necessitate dose reductions. Recent work by our group has found that, often, diarrhea doesn’t develop until after approximately one week of therapy, and so it shouldn’t be assumed that higher doses will be well-tolerated until 1-2 weeks of therapy have passed without gastrointestinal side effects. In stable patients, a low end starting dose of 10 mg/kg twice daily is probably advisable. Mycophenolate mofetil appears to have variable oral bioavailability in dogs, so variability in response to therapy should probably be expected. An older pharmacodynamic study in dogs measuring inosine monophosphate dehydrogenase enzyme activity suggested
that mycophenolate mofetil would best be dosed three times daily, but this recommendation has not entered
common usage. Mycophenolate mofetil has not been used widely enough in veterinary medicine to establish the
frequency of serious side effects but, in people, gastrointestinal signs and, less commonly, marked
myelosuppression and a rare and fatal neurologic disease (progressive multifocal leukoencephalopathy) have been
reported. Based on the human side effect profile, complete blood counts should probably be regularly monitored
in dogs receiving mycophenolate mofetil. In humans, gastrointestinal side effects can be reduced by replacing
mycophenolate mofetil with mycophenolate sodium, but this does not appear to help reduce gastrointestinal side
effects in dogs. Mycophenolic acid in humans is primarily excreted conjugated to glucuronide and, since cats lack
the glucuronyl transferases responsible for glucuronidation of drugs such as mycophenolate mofetil, concern has
been expressed that the drug should used with caution, if at all, in this species. However, the use of
mycophenolate mofetil has been described at a dose rate of 10 mg/kg twice daily, with no obvious side effects, in
two cats with IMHA. Recent work at Washington State University, reassuringly, has found that cats seem to be
able to metabolize mycophenolate rapidly, by actually utilizing glucosidation rather than glucuronidation.